Kevin Gade
Kevin Gade is the Chief Operating Officer at Bahl & Gaynor, an investment management firm. He recently gained attention for his comments on Eli Lilly's experimental weight-loss pill, orforglipron, which showed promising results in clinical trials, suggesting that the data bodes well for future trials and market prospects.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Canada | 1 | 9.00 | 0.04% | +0% | 38,005,238 | 16,662 | $1,700,000 | 745$ |
| Australia | 1 | 8.00 | 0.05% | +0% | 25,499,884 | 12,463 | $1,380,000 | 674$ |
| Totals | 2 | 63,505,122 | 29,125 | $3,080,000 | 1,419$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Australia:
Kevin Gade is the chief operating officer at Bahl & Gaynor, which owns Lilly shares.
8
Canada:
Kevin Gade, chief operating officer at Bahl & Gaynor, stated that the data is fantastic from an efficacy standpoint.
9